Tagged with EALTH

Pharma Leo de Haan of Aurobindo discusses how to maintain a profitable business in times of rock-bottom generics prices in the Netherlands, the resulting second pillar of specialty products for the company and the growth ambitions for the affiliate over the next few years. You have extensive experience in the generics…

Pharma Country Manager Giovanna Labbate talks how Gedeon Richter aims to become the point of reference for women’s health in Italy, the successful launch of ESMYA, and the establishment of the affiliate five years ago. The Gedeon Richter Italy affiliate was established in 2011. What was the rationale behind starting this…

Pharma Despite lacking a national champion to bolster its innovative eco-system since the 2007 acquisition of Organon by Schering Plough, the Netherlands nevertheless still sits in fourth position on the 2015 Global Innovation Index. For the healthcare sector, the country’s innovation is notably propelled by a myriad of local success-stories, and…

Pharma In keeping with its reputation as a forerunner, the Dutch healthcare eco-system is currently reinventing itself to ensure it remains ahead of the game in terms of both innovation and excellence. Market and patient access, transparency, cost-effectiveness and process innovation all feature prominently as industry and government alike band together…

Pharma The Netherlands is clearly a fertile environment for its 2,200 life science and medtech companies. However, the Dutch ambition to be a frontrunner in new healthcare challenges also comprises an overall approach to treating patients. Aging population, chronic disease, and innovative pharmaceutical treatments’ role in extending patients’ life expectancies have…

Pharma Boston Scientific is raising the bar for medical devices and services in the field of cardiology and other pathologies, including Rhythm Management, Endoscopy, Urology Pelvic Health, and Neurostimulation. European President Eric Thépaut shares why Europe has been dubbed the company’s “growth lab”. Boston Scientific has positioned itself to pave the…

Pharma The Director-General of the Gustave Roussy Institute, a top cancer institute in Europe, talks about the revamping of their clinical research infrastructure to adapt to the rising new field of translational research and his ambitious plans for the next five years, in particular, his vision for Cancer Core Europe, positioned…

Pharma The pharmaceutical industry needs to work harder to demonstrate the value that it delivers to society and to the greater economy by advancing public health outcomes, delegates at the 14th annual eyeforpharma conference in Barcelona have been told. Addressing over a thousand industry stakeholders at Barcelona’s Centre Convencions Internacional, senior…

Pharma Carlos Jaime, Head of Samsung’s Health & Medical Equipment Division, France, explains why the future of healthcare is in mobile technology and communications, and how Samsung’s expertise in “digital transformations” position the company as a catalyst for change in the industry. The mobile health solution industry is clearly a major…

Pharma In part II of an exclusive interview at the eyeforpharma Barcelona Summit 2016, IMS Health’s Chief Digital Officer Richie Etwaru lifts the lid on the concept of Orchestrated Customer Engagement (OCE) and explains how it can demonstrably advance the ideals of patient centrality, inter-stakeholder trust and industry-wide operability. You have been pioneering…

Pharma In an exclusive discussion with Focus Reports, Egyptian Minister of Health, Dr. Ahmed El Din Rady sets out his blueprint for improving the nation’s welfare and securing positive public health outcomes with a 4-point plan based on human capital development, accessibility, countering hepatitis C, and large-scale infrastructural intervention. My foremost…

Pharma In an exclusive interview at the eyeforpharma Barcelona Summit 2016, GSK’s Danie Du Plessis speaks out about patient-centricity and the growing role of medical affairs in the pharma industry. In your speech today, you mentioned that the concept of patient-centrality has not changed, but that expectations around it have; could you…